Unlock instant, AI-driven research and patent intelligence for your innovation.

Method for preparing ticagrelor and intermediate of ticagrelor

A technology for ticagrelor and a compound is applied in the field of preparing ticagrelor and its intermediates, and can solve the problems of being difficult to cure, affecting the quality of ticagrelor products, and the like

Active Publication Date: 2014-06-11
BRIGHTGENE BIO MEDICAL TECH (SUZHOU) CO LTD
View PDF6 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0018] Compared with the method disclosed in WO0192263, the method uses nitro to replace the amino group on the pyrimidine ring, which makes the first step reaction easier to carry out, the reaction conditions are optimized, and the entire reaction process is shortened; but there are still intermediates that are oily and difficult to solidify. Defects affecting the quality of ticagrelor products

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method for preparing ticagrelor and intermediate of ticagrelor
  • Method for preparing ticagrelor and intermediate of ticagrelor
  • Method for preparing ticagrelor and intermediate of ticagrelor

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0072] Example 1 compound 2-b’ synthesis

[0073]

[0074] In a 250ml single-necked round bottom flask, add 160ml of ethanol, 60ml (0.70mol) of 36%-38% concentrated hydrochloric acid, compound 2-a’ 20g (0.05mol), stirred overnight at room temperature. Compounds detected by TLC 2-a’ After the reaction is complete, post-treatment is carried out. 40% sodium hydroxide aqueous solution was added dropwise under ice-cooling to neutralize the reaction solution to Ph=6-7. After the ethanol was distilled off under reduced pressure, 200 ml of ethyl acetate was added to extract the aqueous phase three times. The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the ethyl acetate solvent was distilled off under reduced pressure to obtain 2-b’ The product was 14 g of light yellow oily matter, the yield was 77.8%, and the HPLC purity was greater than 98%. 1 H NMR (400M, CDCl 3 ) δ: 7.30-7.34 (m, 5H), 5.4 (s, 2H), 4.22 (s, 2H), 4.12 (...

Embodiment 2

[0075] Example 2 compound 2-c’ synthesis

[0076]

[0077] compound 2-b’ 4g (11.3mmol) and 5.5g (68.9mmol) of pyridine were dissolved in 20ml of dichloromethane, and the temperature was lowered to -80°C under the protection of nitrogen. Dissolve 2g (6.7mmol) of bis(trichloromethyl)carbonate in 20ml of dichloromethane, and slowly add it dropwise to the above reaction solution. The temperature of the dropwise addition process was controlled at -80°C. After the dropwise addition, continue to stir for 30 minutes, then slowly warm up to room temperature and continue to stir for 30-60 minutes. Compounds detected by TLC 2-b’ After the reaction is complete, post-treatment is carried out. The reaction was terminated by adding a saturated ammonium chloride aqueous solution dropwise until no bubbles were generated in the reaction solution. Separate the layers, and wash the organic phase with 1mol / L hydrochloric acid. Separate the liquid, and wash the organic phase with water. ...

Embodiment 3

[0078] Example 3 Compound 2-d’ synthesis

[0079]

[0080] Add 1.32ml (2.64mmol) of 2mol / L LiBH4 solution in THF to a 100ml three-neck round bottom flask, and cool down to -10°C. Under nitrogen protection, the compound 2-c’ 1g (2.64mmol) was dissolved in 5ml THF, and slowly added dropwise to the above solution. Stirring was continued for 2 hours after the dropwise addition was complete. Compounds detected by TLC 2-c After the reaction is complete, post-treatment is carried out. The reaction solution was poured into ice water, stirred for 15 minutes, and 10 ml of ethyl acetate was added to extract the aqueous phase twice. The ethyl acetate phases were combined, dried over anhydrous sodium sulfate, filtered, and the solvent was evaporated under reduced pressure to obtain the compound 2-d’ The crude product was 0.8g, and the compound was obtained after separation by column chromatography (silica gel column, eluent petroleum ether: ethyl acetate = 3:2) 2-d’ The product ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a compound which is shown as a formula (2) and serves as a drug intermediate, a method for preparing the compound shown as the formula (2) and use of the compound shown as the formula (2) in preparation of triazolopyrimidine compounds.

Description

technical field [0001] The invention relates to a preparation method of a novel anticoagulant drug ticagrelor and an intermediate thereof. Background technique [0002] Ticagrelor (trade name Brilinta, CAS: 274693-27-5), chemical name: (1S,2S,3R,5S)-3-[7-[(1R,2S)-2-(3,4-di Fluorophenyl)cyclopropylamino]-5-(propylthio)-3H-[1,2,3]triazol[4,5-d]pyrimidin-3-yl]-5-(2-hydroxyethoxy base) cyclopentane-1,2-diol, the structural formula is shown in the following formula (I): [0003] [0004] (I) [0005] Ticagrelor is a new oral selective small molecule anticoagulant drug developed by AstraZeneca. The drug can reversibly act on the P2Y of platelets 12 Receptor, can strongly inhibit platelet aggregation caused by adenosine diphosphate (ADP). Because of its rapid onset after oral administration, it can obviously improve the symptoms of patients with acute coronary heart disease. Compared with clopidogrel, it has anti-platelet aggregation activity itself and does not require m...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07D487/04C07D317/44C07D405/12
CPCC07D317/44C07D405/12C07D487/04
Inventor 袁建栋姜桥李响
Owner BRIGHTGENE BIO MEDICAL TECH (SUZHOU) CO LTD